Last Week in Biomedicine | May 4-9

Last week's biggest biotech story: Cytokinetics hit both dual primary endpoints in the ACACIA-HCM pivotal Phase 3 trial of aficamten in non-obstructive hypertrophic cardiomyopathy — the first cardiac myosin inhibitor to win in nHCM and a major franchise expansion. Moderna's mRNA-1010 flu vaccine also landed in NEJM, and DDW 2026 drove a cluster of IBD readouts.

This week we cover:

1. Cytokinetics ($CYTK) — aficamten for non-obstructive hypertrophic cardiomyopathy (Phase 3)

2. Moderna ($MRNA) — mRNA-1010 seasonal influenza vaccine (Phase 3)

3. Avalo Therapeutics ($AVTX) — abdakibart (AVTX-009) for hidradenitis suppurativa (Phase 2)

4. Viridian Therapeutics ($VRDN) — elegrobart for chronic thyroid eye disease (Phase 3)

5. Johnson & Johnson ($JNJ) — JNJ-4804 (guselkumab + golimumab) for refractory ulcerative colitis and Crohn's disease (Phase 2b)

6. Bayer ($BAYRY) — asundexian for secondary stroke prevention (Phase 3 OCEANIC-STROKE late-breaking)

7. AbbVie ($ABBV) — risankizumab (Skyrizi) and upadacitinib (Rinvoq) long-term IBD data (Phase 3)

8. Eli Lilly ($LLY) — mirikizumab (Omvoh) long-term IBD data (Phase 3)

9. Nuance Pharma (private) — nafithromycin (MIQNAF) for community-acquired bacterial pneumonia (Phase 3)

10. Bioxodes (private) — BIOX-101 for intracerebral hemorrhage (Phase 2a)

The Cytokinetics nHCM win opens up a second indication for aficamten and pressures BMS's Camzyos directly, while Moderna's NEJM publication strengthens its bid for FDA approval and a seasonal flu commercial launch. DDW 2026 was a watershed for combination biologic IBD therapy.

Subscribe for weekly clinical trial breakdowns at TrialBreaks.com

#biotech #clinicaltrials #pharma #cardiology #HCM #obesity #vaccines #mRNA #immunology #IBD #ulcerativecolitis #Crohns #neurology #stroke #dermatology #hidradenitis #thyroideyedisease #infectiousdisease

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(17)

Last Week in Biomedicine | Jun 29–Jul 3 | Part 2 of 2: Baby Pompe Disease Trial, DLBCL Combo Win

Part 2 covers three more standout stories from the same week: a Phase 3 trial that gives babies with a devastating enzyme disease a fighting chance, a first-of-its-kind cell therapy approved to make b...

9 Jul 36min

Last Week in Biomedicine | Jun 29–Jul 3 | Part 1 of 2: CRISPR for Toddlers, KRAS Lung Cancer Win

CRISPR gene editing crossed a major line this week: the FDA now allows Casgevy — the first CRISPR therapy of any kind — for children as young as 2 with sickle cell disease, meaning we can potentially ...

7 Jul 43min

Last Week in Biomedicine | June 22–26 | Part 2 of 2: Thyroid Eye Disease, ADHD + Anxiety, Skyrizi Kids

Part 2 covers a new drug for the bulging-eye autoimmune disease, the first Phase 3 ADHD trial designed for patients who also have anxiety, and a major pediatric expansion for a top-selling psoriasis b...

2 Jul 41min

Last Week in Biomedicine | June 22–26 | Part 1 of 2: LSD Depression Phase 3, Trodelvy TNBC Approval

This week, an LSD-based therapy hit its main goal in a Phase 3 depression trial — and two huge breast cancer approvals landed at the FDA on the same week. In Part 1 we cover:1. Definium Therapeutics —...

30 Jun 36min

Last Week in Biomedicine | June 14–20 | Part 2 of 2: Mezigdomide Myeloma, HCM Heart Drug

Part 2 of our week of June 14–20, 2026 wrap-up covers a new molecular glue for relapsed multiple myeloma that cut disease progression by half, a heart drug that may finally work forboth forms of hyper...

25 Jun 25min

Last Week in Biomedicine | June 14–20 | Part 1 of 2: CRISPR HAE Cure, Narcolepsy Orexin Breakthrough

This week opened with one of the most significant gene-editing milestones in clinical medicine: a single CRISPR infusion cut hereditary angioedema attacks by 87 percent in a Phase 3 trial, published t...

23 Jun 34min

Last Week in Biomedicine | June 6–13 | Part 2 of 2: CagriSema Diabetes, Sickle Cell Plenary

Part 2 of our June 6–13 wrap-up: Novo Nordisk's CagriSema beats semaglutide alone in three Phase 3 diabetes trials, Takeda's zasocitinib pill outperforms Sotyktu head-to-head in psoriasis, and Agios's...

18 Jun 21min

Last Week in Biomedicine | June 6–13 | Part 1 of 2: Retatrutide Weight Loss, Weekly HIV Pill

A blockbuster week in biomedicine — Eli Lilly's retatrutide produced weight loss approaching bariatric surgery in Phase 3, and Gilead and Merck's once-weekly oral HIV pill cleared two Phase 3 trials. ...

16 Jun 20min